Equillium, Inc.
EQAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| May 28, 2026 | Raymond James | $7.00(+138%) | $2.94 | TheFly | |
| May 28, 2026 | Stifel Nicolaus | Alex Thompson | $5.00(+90%) | $2.63 | StreetInsider |
| May 28, 2026 | Leerink Partners | Thomas Smith | $6.00(+128%) | $2.63 | StreetInsider |
| Apr 23, 2026 | Oppenheimer | $7.00(+200%) | $2.33 | TheFly | |
| Apr 13, 2026 | Raymond James | $6.00(+253%) | $1.70 | TheFly | |
| Mar 28, 2025 | Leerink Partners | Thomas Smith | $1.00(+150%) | $0.40 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Roth Capital | maintain | Buy | Sep 4, 2026 |
| Roth Capital | maintain | Buy | Jun 2, 2026 |
| Leerink Partners | upgrade | Market Perform →Outperform | May 28, 2026 |
| Roth Capital | maintain | Buy | May 28, 2026 |
| Roth Capital | maintain | Buy | Apr 17, 2026 |
| Leerink Partners | downgrade | Outperform →Market Perform | Mar 28, 2025 |
| Jones Trading | downgrade | Buy →Hold | Nov 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 19, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 17, 2024 |
| HC Wainwright & Co. | maintain | Buy | Apr 2, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 26, 2023 |
| HC Wainwright & Co. | maintain | Buy | Nov 13, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Aug 14, 2023 |
| HC Wainwright& Co. | maintain | Buy | Aug 14, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 14, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 1, 2023 |
| Stifel | maintain | Buy | Mar 24, 2023 |
| SVB Leerink | maintain | Outperform | Feb 8, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 27, 2022 |
| SVB Leerink | maintain | Outperform | Sep 8, 2022 |
| HC Wainwright & Co. | maintain | Buy | Mar 24, 2022 |
| SVB Leerink | maintain | Outperform | Jan 5, 2022 |
| Cantor Fitzgerald | maintain | Overweight | Sep 15, 2021 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.05| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.04 | $-0.05 | — | — |
| May 13, 2026 | $-0.06 | $-0.04 | — | — |
| Mar 25, 2026 | $-0.04 | $-0.07 | — | — |
| Nov 13, 2025 | $-0.06 | $-0.14 | — | — |
| Aug 14, 2025 | $-0.16 | $-0.14 | — | — |
| May 14, 2025 | $-0.24 | $-0.23 | — | — |
| Mar 27, 2025 | $-0.16 | $-0.22 | $4.4M | — |
| Nov 13, 2024 | $-0.00 | $-0.26 | $12.2M | $11.6M |
News
Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027 Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504 Triggers Milestone Closing of $20 million in additional funding under previously announced equity private placement agreement; cash expected to fund currently planned operations into 2029 LA JOLLA, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat…
New preclinical data further characterizes EQ504's coordinated effects across epithelial and immune compartments in intestinal inflammation New preclinical data further characterizes EQ504's coordinated effects across epithelial and immune compartments in intestinal inflammation
On track to initiate dosing by early November 2026; topline Phase 1 proof-of-mechanism data anticipated approximately six months following study initiation
New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation New preclinical data further characterize EQ504's effects on epithelial barrier repair and immune regulation
Equillium (NASDAQ: EQ) Chief Scientific Officer Stephen Connelly outlined the company's plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative colitis and an oral bispecific peptide for celiac disease, during a fireside chat. Connelly said the company, founded in 2017 and public since 2018, has focused on developing
Equillium NASDAQ: EQ Chief Scientific Officer Stephen Connelly outlined the company's plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative colitis and an oral bispecific peptide for celiac disease, during a fireside chat.
LA JOLLA, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be participating in a fireside chat at Stifel's 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026 at 12:00pm EDT.
Australian miner EQ Resources said on Tuesday it would take a 10% stake in a joint venture with Nasdaq-listed Elmet Group and Blue Moon Metals to restart the Springer tungsten project in Nevada.
LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026 Format: Fireside Chat & 1x1 MeetingsDate: Wednesday, September 9, 2026Time: 9:45 AM EDTWebcast Link: Here H.C.
Phase 1 proof-of-mechanism study of EQ504 initiation expected in Q4 2026, with data expected approximately six months thereafter Cash and cash equivalents of $57.2 million expected to fund operations into 2029 LA JOLLA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders, today reported financial results for the second quarter end…
Shares of Equillium, Inc. (NASDAQ: EQ - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven research firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, seven have assigned a buy recommendation and two have assigned a strong buy recommendation to